Compositions and methods for combination therapy with dengue virus and dendritic cells

Abstract

Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.

What is claimed is: 
     
         1 . A method for reducing or treating cancer, the method comprising administering to a subject having cancer:
 an effective amount of Dengue Virus; and   dendritic cells, to the subject, wherein the dendritic cells are administered more than once.   
     
     
         2 . The method of  claim 1 , wherein the dendritic cells are tumor antigen primed. 
     
     
         3 . The method of  claim 2 , wherein a tumor cell lysate that comprises a tumor antigen is used to prime the dendritic cells. 
     
     
         4 . The method of  claim 2 , wherein a tumor cell lysate that comprises a non-tumor antigen is used to prime the dendritic cells. 
     
     
         5 . The method of  claim 4 , wherein the non-tumor antigen is from a cell of the tumor microenvironment. 
     
     
         6 . The method of  claim 1 , further comprising a second administration of the dendritic cells. 
     
     
         7 . The method of  claim 4 , wherein the administration and the second administration are separated by at least 3 weeks. 
     
     
         8 . The method of  claim 1 , wherein the Dengue Virus is of serotype DENV-1, DENV-2, DENV-3, DENV-4, or DENV-5. 
     
     
         9 . The method of  claim 8 , wherein the Dengue Virus is of serotype DENV-1. 
     
     
         10 . The method of  claim 1 , wherein the cancer is a solid cancer. 
     
     
         11 . The method of  claim 10 , wherein the solid cancer is skin cancer. 
     
     
         12 . The method of  claim 1 , wherein the dendritic cells are autologous. 
     
     
         13 . A method for reducing or treating metastatic cancer, the method comprising administering to a subject having metastatic cancer:
 an effective amount of Dengue Virus; and   dendritic cells, to the subject, wherein the dendritic cells are administered more than once.   
     
     
         14 . The method of  claim 13 , wherein the reduction or treatment of the metastatic cancer comprises a reduction in metastases. 
     
     
         15 . The method of  claim 14 , wherein the metastases are in the lungs of the subject. 
     
     
         16 . The method of  claim 13 , wherein the metastatic cancer is skin cancer. 
     
     
         17 . The method of  claim 16 , wherein the skin cancer is melanoma. 
     
     
         18 . The method of  claim 13 , wherein the dendritic cells are autologous. 
     
     
         19 . The method of  claim 13 , further comprising a second administration of the dendritic cells at least 3 weeks after the administering. 
     
     
         20 . The method of  claim 13 , wherein the Dengue Virus is of serotype DENY-1, DENV-2, DENV-3, DENV-4, or DENV-5.